📢Market Bulletin
Drug & Salt Regulations (3)
Category Archive →ICH Q14 & Q2(R2) Analytical Procedure Development & Validation Standards for Generic Drug Master Files
Regulatory adoption briefing for the revised ICH Q14 (Analytical Procedure Development) and ICH Q2(R2) (Validation of Analytical Procedures) guidelines governing Active Substance Master Files (ASMFs) and US DMFs. Validation Scope: Expanded multivariate analytical design incorporating Analytical Target Profiles (ATP), HPLC/UPLC gradient robustness, and System Suitability Testing (SST) for assay and related substances. Lifecycle Management: Established Conditions (ECs) for analytical procedures allow structured post-approval change management under ICH Q12 frameworks. Official Source & Verification Reference Issuing Authority: International Council for Harmonisation (ICH) • Reference: ICH-Q14-Q2R2-STEP5 Verify Official Source Document ↗
USP–NF Compendial Compliance: Elemental Impurities <232>/<233> & Dissolution Testing for Oral Salts
Compendial enforcement notice for bulk pharmaceutical salts and finished tablets exported to USP-recognized jurisdictions. All drug products must demonstrate full alignment with USP General Chapters <232> and <233> , harmonized with ICH Q3D(R2) elemental impurity guidelines. Class 1 & 2A Metals: Mandatory ICP-MS or ICP-OES risk assessment covering Cadmium (Cd), Lead (Pb), Arsenic (As), Mercury (Hg), Cobalt (Co), Nickel (Ni), and Vanadium (V) from synthesis catalysts and primary packaging leachables. Batch Release: Generic API Certificates of Analysis (COA) must specify analytical method reference, loss on drying (LOD), and residue on ignition thresholds. Official Source & Verification Reference Issuing Authority: United States Pharmacopeia (USP) • Reference: USP-NF-232-233-2026 Verify Official Source Document ↗
EMA Nitrosamine Impurity Assessment: Confirmatory Acceptable Intake (AI) Limits for Sartan & Metformin APIs
Mandatory regulatory update concerning N-nitrosamine and Nitrosamine Drug Substance-Related Impurities (NDSRIs) in cardiovascular and antihyperglycemic molecules ( HS Code 2933.99 and HS Code 2925.29 ). Marketing authorization holders and API manufacturers must apply the Carcinogenic Potency Categorization Approach (CPCA). Analytical Thresholds: Validated LC-MS/MS or GC-MS/MS methods capable of quantifying NDMA, NDEA, and NDSRI variants down to 10% of the compound-specific Acceptable Intake (AI) limit (typically 18–100 ng/day). Excipient Control: Mandatory screening of nitrite levels in microcrystalline cellulose, povidone, and starch excipients to prevent in-situ nitrosation during granulation. Official Source & Verification Reference Issuing Authority: European Medicines Agency (EMA) • Reference: EMA/409815/2020-Rev.2026 Verify Official Source Document ↗
